Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Epidermal growth factor (EGF) is a molecule with a broad pharmacological activity which has been used clinically, with promising results, to treat patients affected by necrotizing enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy. In theory, EGF may find a clinical application in a variety of other pathologies of both the gastrointestinal tract and other systems. Examples of gastrointestinal diseases that could benefit from treatment with EGF include colitis, gastrointestinal ulcerations of various causes, atrophic conditions, conditions of defective maturation and development and even cancer. However, the clinical use of EGF may be associated with a variety of problems and side-effects; careful selection of patients and evaluation of risk-benefit ratios are required.

Original publication

DOI

10.1097/00042737-199510000-00007

Type

Journal

Eur J Gastroenterol Hepatol

Publication Date

10/1995

Volume

7

Pages

945 - 950

Keywords

Adult, Child, Epidermal Growth Factor, Forecasting, Gastrointestinal Diseases, Humans, Infusions, Intravenous, Recombinant Proteins, Treatment Outcome, Wound Healing